Sustained Release Recombinant Human Growth Hormone

Recombinant Human Growth Hormone (rhGH) therapies have been successfully used to treat growth hormone deficiencies for 20 years. All current formulations require daily administration by subcutaneous injection, administered at home by the patient or parent. Although therapy is in general highly successful, the daily regimen and dislike of injections leads in some cases to non-compliance and therefore ineffective therapy at great cost to the healthcare provider.

To counter this and to realise an unmet medical need, Biopartners has developed a once-a-week-prolonged release formulation of recombinant human growth hormone. Over a typical 5 year treatment period, Biopartners’ once-a-week prolonged release rhGH would save over 1500 injections compared to standard daily therapy. Since most patients are young children and therefore particularly concerned about injections, this innovative product is a major breakthrough in Growth Hormone therapy, providing greater convenience, acceptability and improved compliance compared with daily hGH preparations. 

Biopartners' prolonged-release rhGH is the first once-a-week somatropin containing medicinal product to have received the marketing authorisation in the EU, Norway and Iceland.